FCGR2B and neoplasm: Only FCGR2B has been identified to be selectively expressed by metastasis melanoma that impairs the tumor susceptibility to FcγR-dependent innate effector responses, which might explain in part the low response of melanoma patients treated with anti-idiotype (38).